These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 36653904)

  • 1. Genetic alterations of GI-NECs involving three main signaling pathways.
    Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
    Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
    Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms.
    Duan X; Zhao M; Yin X; Mi L; Shi J; Li N; Han X; Han G; Wang J; Hou J; Yin F
    Cancer Med; 2023 Aug; 12(15):16207-16220. PubMed ID: 37387515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
    Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
    Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
    Scarpa A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.
    Park HK; Kwon GY
    J Korean Med Sci; 2023 Mar; 38(11):e85. PubMed ID: 36942393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas.
    Cubiella T; Celada L; San-Juan-Guardado J; Rodríguez-Aguilar R; Suárez-Priede Á; Poch M; Dominguez F; Fernández-Vega I; Montero-Pavón P; Fraga MF; Nakatani Y; Takata S; Yachida S; Valdés N; Chiara MD
    J Pathol; 2024 Aug; 263(4-5):418-428. PubMed ID: 38795318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
    Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
    Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and prevalence of neuroendocrine neoplasms in Norway 1993-2021.
    Thiis-Evensen E; Boyar Cetinkaya R
    J Neuroendocrinol; 2023 Apr; 35(4):e13264. PubMed ID: 36988112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
    Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
    J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM
    Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and molecular characteristics of neuroendocrine carcinomas of the gallbladder.
    Tang H; Jiang X; Zhu L; Xu L; Wang X; Li H; Gao F; Liu X; Ren C; Zhao Y
    Histol Histopathol; 2024 Jul; ():18788. PubMed ID: 39041213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System.
    Yachida S; Totoki Y; Noë M; Nakatani Y; Horie M; Kawasaki K; Nakamura H; Saito-Adachi M; Suzuki M; Takai E; Hama N; Higuchi R; Hirono S; Shiba S; Kato M; Furukawa E; Arai Y; Rokutan H; Hashimoto T; Mitsunaga S; Kanda M; Tanaka H; Takata S; Shimomura A; Oshima M; Hackeng WM; Okumura T; Okano K; Yamamoto M; Yamaue H; Morizane C; Arihiro K; Furukawa T; Sato T; Kiyono T; Brosens LAA; Wood LD; Hruban RH; Shibata T
    Cancer Discov; 2022 Mar; 12(3):692-711. PubMed ID: 34880079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
    Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
    Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
    Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
    Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
    Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
    Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Angerilli V; Sabella G; Simbolo M; Lagano V; Centonze G; Gentili M; Mangogna A; Coppa J; Munari G; Businello G; Borga C; Schiavi F; Pusceddu S; Leporati R; Oldani S; Fassan M; Milione M
    Br J Cancer; 2024 Jul; 131(1):159-170. PubMed ID: 38729995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.